HRP20171978T1 - Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 - Google Patents
Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 Download PDFInfo
- Publication number
- HRP20171978T1 HRP20171978T1 HRP20171978TT HRP20171978T HRP20171978T1 HR P20171978 T1 HRP20171978 T1 HR P20171978T1 HR P20171978T T HRP20171978T T HR P20171978TT HR P20171978 T HRP20171978 T HR P20171978T HR P20171978 T1 HRP20171978 T1 HR P20171978T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- cells
- human
- cell
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Humano specifično anti-CD38 antitijelo koje sadrži:
(i) H-CDR1, H-CDR2 i H-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 21, i L-CDR1, L-CDR2 i L-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 51;
(ii) varijabilni teški lanac sekvence SEQ ID NO: 21, i varijabilni laki lanac sekvence SEQ ID NO: 51; ili
(iii) varijabilni teški lanac kodiran sekvencom SEQ ID NO: 6, i varijabilni laki lanac kodiran sekvencom SEQ ID NO: 36.
2. Antitijelo prema patentnom zahtjevu 1, naznačeno time što antitijelo predstavlja IgG, poželjno IgG1.
3. Kompozicija nukleinske kiseline koja sadrži sekvencu nukleinske kiseline ili mnoštvo sekvenci nukleinske kiseline koje kodiraju antitijelo prema patentnom zahtjevu 1 ili 2.
4. Vektorska kompozicija koja sadrži vektor ili mnoštvo vektora koji sadrže sekvencu nukleinske kiseline, ili mnoštvo sekvenci nukleinske kiseline, prema patentnom zahtjevu 3.
5. Stanica koja sadrži vektorsku kompoziciju prema patentnom zahtjevu 4, gdje je stanica izborno bakterijska stanica ili stanica sisavca.
6. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač ili ekscipijens.
7. Antitijelo prema patentnom zahtjevu 1 ili 2 za upotrebu u liječenju hematološke bolesti ili inflamatorne bolesti.
8. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač ili ekscipijens za upotrebu u liječenju hematološke bolesti ili inflamatorne bolesti.
9. Antitijelo, za upotrebu prema patentnom zahtjevu 7 ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 8, naznačena time što je navedena hematološka bolest izabrana s liste na kojoj se nalaze multipli mijеlom, kronična limfocitna leukemija, kronična mijeloidna leukemija, akutna mijeloidna leukemija i akutna limfocitna leukemija.
10. Antitijelo, za upotrebu prema patentnom zahtjevu 7 ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 8, naznačena time što je navedena inflamatorna bolest izabrana sa liste na kojoj se nalazе reumatoidni artritis i sistemski lupus eritematozus.
11. In vitro postupak za indukciju specifičnog uništavanja tumorskih stanica koje eksprimiraju CD38, naznačen time što se navedeno specifično uništavanje odvija putem križnog vezivanja CD38, koje obuhvaća korak inkubacije navedenih stanica u prisutnosti dovoljne količine antitijela prema patentnom zahtjevu 1 ili 2.
12. Postupak za detekciju specifičnog uništavanja tumorskih stanica koje eksprimiraju CD38, putem križnog vezivanja CD38, kod subjekta kod koga je primijenjeno antitijelo prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifične aktivnosti uništavanja kod navedenog antitijela, gdje tumorske stanice izborno potiču od čovjeka, mini-svinje ili zeca.
13. Postupak za detekciju prisustva CD38 u tkivu ili u stanici koja potiče od mini-svinje dovedenој u kontakt sa antitijelom prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifičnog vezivanja navedenog antitijela za navedene CD38 stanice mini-svinje, gdje je navedeno antitijelo takođe sposobno da se specifično veže za CD38 humanog porekla, pri čemu je izborno, CD38 poreklom od mini-svinje, sadržan u tipu izolovane stanice izabranom iz grupe koja se sastoji od monocita periferne krvi, eritrocita, limfocita, timocita, mišićne stanice, stanice cerebeluma, stanice pankreasa, stanice limfnog čvora, stanice tonzila, stanice slezine, stanice prostate, stanice kože i stanice retine.
14. Postupak za detekciju CD38 u eritrocitu koji eksprimira CD38 dovedenom u kontakt sa antitijelom prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifičnog vezivanja navedenog antitijela za navedene eritrocite koji eksprimiraju CD38, naznačen time što je navedeno antitijelo takođe sposobno da se specifično veže za humani CD38 iz stanice ili tkiva koje nisu humani eritrociti, gdje je izborno antitijelo takođe sposobno da se specifično veže za humani CD38 iz stanice koja je humani limfocit.
15. Dijagnostička kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i prihvatljiv nosač ili ekscipijens
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72529705P | 2005-10-12 | 2005-10-12 | |
| EP14196972.5A EP2860192B1 (en) | 2005-10-12 | 2006-10-12 | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171978T1 true HRP20171978T1 (hr) | 2018-04-06 |
Family
ID=37467440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171978TT HRP20171978T1 (hr) | 2005-10-12 | 2017-12-20 | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8088896B2 (hr) |
| EP (3) | EP3284756B1 (hr) |
| JP (2) | JP5362359B2 (hr) |
| KR (4) | KR101472250B1 (hr) |
| CN (4) | CN101287764B (hr) |
| AR (2) | AR055191A1 (hr) |
| AU (1) | AU2006301446B2 (hr) |
| BR (1) | BRPI0618399B1 (hr) |
| CA (1) | CA2625681C (hr) |
| CY (1) | CY1119722T1 (hr) |
| DK (1) | DK2860192T3 (hr) |
| ES (1) | ES2653664T3 (hr) |
| HR (1) | HRP20171978T1 (hr) |
| HU (1) | HUE035250T2 (hr) |
| IL (1) | IL190665B (hr) |
| LT (1) | LT2860192T (hr) |
| ME (1) | ME02886B (hr) |
| NO (1) | NO344961B1 (hr) |
| NZ (1) | NZ566915A (hr) |
| PL (1) | PL2860192T3 (hr) |
| PT (1) | PT2860192T (hr) |
| RS (1) | RS56677B1 (hr) |
| RU (1) | RU2425841C2 (hr) |
| SG (1) | SG10201400973XA (hr) |
| SI (1) | SI2860192T1 (hr) |
| TW (1) | TWI428444B (hr) |
| WO (1) | WO2007042309A2 (hr) |
| ZA (1) | ZA200803208B (hr) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| NZ597692A (en) | 2008-12-12 | 2013-08-30 | Boehringer Ingelheim Int | Anti-IGF antibodies |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| DK2621531T3 (en) | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| WO2013010955A1 (en) * | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| EP2843051B1 (en) * | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| MX368288B (es) * | 2012-09-25 | 2019-09-27 | Morphosys Ag | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| US9845364B2 (en) | 2012-11-09 | 2017-12-19 | Genefrontier Corporation | Anti-ADAM28 antibody for treating cancer |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| BR112015027313A2 (pt) * | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| JP5892117B2 (ja) * | 2013-07-17 | 2016-03-23 | 横河電機株式会社 | フィールド機器及び通信システム |
| CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| TWI584018B (zh) | 2014-08-03 | 2017-05-21 | 帕戈技術股份有限公司 | 穿戴式照相機系統與用於將照相機系統或其他電子裝置附接至穿戴式製品之設備及方法 |
| PH12017500442B1 (en) * | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| CN107614527A (zh) | 2015-03-06 | 2018-01-19 | 基因先端领域株式会社 | 抗人膜类型adam28抗体 |
| US9951144B2 (en) * | 2015-04-08 | 2018-04-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
| HUE054271T2 (hu) | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| IL256242B2 (en) * | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| EA037548B1 (ru) | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| CA3004152C (en) * | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| WO2017149122A1 (en) | 2016-03-04 | 2017-09-08 | Morphosys Ag | Clinical assessment of m-protein response in multiple myeloma |
| WO2017185037A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| WO2018015498A1 (en) | 2016-07-20 | 2018-01-25 | Hybrigenics Sa | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| BR112019013953A2 (pt) | 2017-01-06 | 2020-02-11 | Abl Bio Inc. | Anticorpo anti-a-syn e uso do mesmo |
| CN110997722B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| JP7679196B2 (ja) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| KR102770110B1 (ko) * | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 항체 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3073085A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| BR112020007751A2 (pt) | 2017-10-25 | 2020-10-20 | Acceleron Pharma Inc. | proteínas de ligação de alk7 e usos das mesmas |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| EP3725806A4 (en) * | 2017-12-14 | 2022-03-30 | ABL Bio Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| KR20250099256A (ko) | 2018-01-18 | 2025-07-01 | 프레드 허친슨 캔서 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| US12048745B2 (en) | 2018-05-01 | 2024-07-30 | Augusta University Research Institute, Inc. | Methods for detecting and reversing immune therapy resistance |
| UA130542C2 (uk) | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| CA3103114A1 (en) | 2018-06-20 | 2019-12-26 | Sorrento Therapeutics, Inc. | Variant antibody that binds cd38 |
| US20240254252A1 (en) | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| US20200017600A1 (en) | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| AU2019338999A1 (en) | 2018-09-11 | 2021-03-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| KR20210077725A (ko) | 2018-10-17 | 2021-06-25 | 얀센 바이오테크 인코포레이티드 | 항-cd38 항체의 피하 투여를 제공하는 방법 |
| KR20210086651A (ko) | 2018-10-26 | 2021-07-08 | 테네오바이오, 인코포레이티드 | Cd38에 결합하는 중쇄 항체 |
| EA202191352A1 (ru) | 2018-11-13 | 2021-08-11 | Янссен Байотек, Инк. | Контроль содержания микроэлементов-металлов во время продукции антител к cd38 |
| KR20210104736A (ko) * | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| SG11202107941TA (en) * | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
| AU2020299600A1 (en) | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-CD38 antibody and methods of use thereof |
| JP2022548925A (ja) * | 2019-09-18 | 2022-11-22 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法 |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| JP7811772B2 (ja) * | 2019-12-05 | 2026-02-06 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| CN115023441A (zh) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | 与cd38结合的重链抗体 |
| US20230272105A1 (en) | 2020-01-16 | 2023-08-31 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN113861292A (zh) * | 2020-06-30 | 2021-12-31 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆（苏州）医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| MX2024005392A (es) | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| AU2022380155A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| CN116514974A (zh) * | 2022-01-30 | 2023-08-01 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| IL317689A (en) | 2022-07-15 | 2025-02-01 | Boehringer Ingelheim Int | Binding molecules for cancer treatment |
| TW202432177A (zh) | 2022-10-31 | 2024-08-16 | 丹麥商珍美寶股份有限公司 | Ｃｄ３８抗體及其用途 |
| KR20250097946A (ko) | 2022-11-02 | 2025-06-30 | 얀센 바이오테크 인코포레이티드 | 암을 치료하는 방법 |
| EP4704979A1 (en) | 2023-01-20 | 2026-03-11 | Boehringer Ingelheim International GmbH | Il-12 fc fusion proteins |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2026059919A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| CN119119277B (zh) * | 2024-10-24 | 2025-09-09 | 深圳技术大学 | 一种靶向cd38的纳米抗体、药物组合物及其应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS63502112A (ja) * | 1986-01-03 | 1988-08-18 | コンソリデイテツド・フアーマシユーテイカルズ・リミテツド | メルファラン誘導体 |
| SU1595902A1 (ru) * | 1988-06-30 | 1990-09-30 | Всесоюзный онкологический научный центр АМН СССР | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов |
| US5156951A (en) * | 1989-07-13 | 1992-10-20 | Becton Dickinson And Company | Detecting immunological changes in HIV infected patient samples |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
| US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
| WO1998016245A1 (fr) * | 1996-10-15 | 1998-04-23 | Shionogi & Co., Ltd. | Procede de determination d'un auto-anticorps |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB9903664D0 (en) | 1999-02-17 | 1999-04-14 | Isis Innovation | Adjuvant and cell maturation agent |
| JP2000316578A (ja) | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| CA2424643A1 (en) | 2000-10-17 | 2002-04-25 | Trudeau Institute, Inc. | Cd38 modulated chemotaxis |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
| AU2002307494A1 (en) | 2001-04-24 | 2002-11-05 | Bayer Corporation | Human timp-1 antibodies |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| US7262278B2 (en) * | 2001-10-15 | 2007-08-28 | Kirin Beer Kabushiki Kaisha | Anti-HLA-DR antibody |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003091275A2 (en) | 2002-04-23 | 2003-11-06 | Andrea Savarino | Compositions containing anti-hiv peptides and methods of use |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| CA2542840A1 (en) | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| WO2005087806A2 (en) | 2004-02-13 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cd38 splice variant and uses thereof |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| CA2604844A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Cancer-related genes |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| DK2621531T3 (en) * | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| MX368288B (es) * | 2012-09-25 | 2019-09-27 | Morphosys Ag | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. |
| DK2914302T3 (en) * | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| WO2020202527A1 (ja) | 2019-04-04 | 2020-10-08 | オリンパス株式会社 | 画像記録装置 |
| US12491218B2 (en) | 2019-06-30 | 2025-12-09 | Uplift Food Inc | Prebiotic and probiotic cookie preparation |
| US11920830B1 (en) | 2022-11-11 | 2024-03-05 | Russell Dwayne Mcnally | Tool and method for cleaning and draining a water heater |
-
2006
- 2006-10-12 CA CA2625681A patent/CA2625681C/en active Active
- 2006-10-12 KR KR1020137033870A patent/KR101472250B1/ko active Active
- 2006-10-12 DK DK14196972.5T patent/DK2860192T3/en active
- 2006-10-12 EP EP17193089.4A patent/EP3284756B1/en active Active
- 2006-10-12 KR KR1020087011301A patent/KR101512853B1/ko active Active
- 2006-10-12 PT PT141969725T patent/PT2860192T/pt unknown
- 2006-10-12 SI SI200632232T patent/SI2860192T1/en unknown
- 2006-10-12 NZ NZ566915A patent/NZ566915A/en unknown
- 2006-10-12 BR BRPI0618399-9A patent/BRPI0618399B1/pt active IP Right Grant
- 2006-10-12 JP JP2008534940A patent/JP5362359B2/ja active Active
- 2006-10-12 ME MEP-2017-289A patent/ME02886B/me unknown
- 2006-10-12 LT LTEP14196972.5T patent/LT2860192T/lt unknown
- 2006-10-12 AU AU2006301446A patent/AU2006301446B2/en active Active
- 2006-10-12 CN CN2006800379242A patent/CN101287764B/zh active Active
- 2006-10-12 KR KR1020147020460A patent/KR101574920B1/ko active Active
- 2006-10-12 CN CN201310495574.6A patent/CN103554260A/zh active Pending
- 2006-10-12 EP EP06806243A patent/EP1945671A2/en not_active Withdrawn
- 2006-10-12 KR KR1020157034098A patent/KR20150139636A/ko not_active Ceased
- 2006-10-12 RU RU2008111882/10A patent/RU2425841C2/ru active
- 2006-10-12 CN CN201510918061.0A patent/CN106434683B/zh active Active
- 2006-10-12 RS RS20171300A patent/RS56677B1/sr unknown
- 2006-10-12 TW TW095137628A patent/TWI428444B/zh active
- 2006-10-12 WO PCT/EP2006/009889 patent/WO2007042309A2/en not_active Ceased
- 2006-10-12 AR ARP060104476A patent/AR055191A1/es active IP Right Grant
- 2006-10-12 ES ES14196972.5T patent/ES2653664T3/es active Active
- 2006-10-12 SG SG10201400973XA patent/SG10201400973XA/en unknown
- 2006-10-12 HU HUE14196972A patent/HUE035250T2/hu unknown
- 2006-10-12 EP EP14196972.5A patent/EP2860192B1/en active Active
- 2006-10-12 CN CN201310494874.2A patent/CN103554259B/zh active Active
- 2006-10-12 PL PL14196972T patent/PL2860192T3/pl unknown
- 2006-10-12 US US12/089,806 patent/US8088896B2/en active Active
-
2008
- 2008-04-07 IL IL190665A patent/IL190665B/en active IP Right Grant
- 2008-04-11 ZA ZA200803208A patent/ZA200803208B/xx unknown
- 2008-04-25 NO NO20081972A patent/NO344961B1/no unknown
-
2011
- 2011-11-08 US US13/291,473 patent/US8486394B2/en active Active
-
2012
- 2012-11-08 JP JP2012246686A patent/JP5752667B2/ja active Active
-
2013
- 2013-06-14 US US13/918,199 patent/US9193799B2/en active Active
-
2015
- 2015-10-08 US US14/877,958 patent/US10184005B2/en active Active
-
2016
- 2016-07-26 AR ARP160102271A patent/AR105490A2/es not_active Application Discontinuation
-
2017
- 2017-12-19 CY CY20171101331T patent/CY1119722T1/el unknown
- 2017-12-20 HR HRP20171978TT patent/HRP20171978T1/hr unknown
-
2018
- 2018-09-07 US US16/125,307 patent/US11059902B2/en active Active
-
2021
- 2021-06-09 US US17/343,163 patent/US11939395B2/en active Active
-
2024
- 2024-01-22 US US18/418,804 patent/US20240309109A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171978T1 (hr) | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 | |
| Wu et al. | Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis | |
| JP5893559B2 (ja) | 新規な薬剤及びその使用 | |
| Spiegel et al. | Neutrophils suppress intraluminal NK cell–mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells | |
| Sanchez-Martinez et al. | Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors | |
| Avigdor et al. | CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow | |
| Zhang et al. | Ongoing activation of autoantigen‐specific B cells in primary biliary cirrhosis | |
| RU2015108348A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| UA126802C2 (uk) | Композиція, що містить антигензв’язуючий домен, який зв'язується з tigit людини | |
| JP6830471B2 (ja) | 抗ホスホリパーゼｄ４抗体 | |
| JP2007504280A5 (hr) | ||
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| DE60237778D1 (de) | Antikörper gegen kdr, deren herstellung und verwendungen | |
| RU2010129423A (ru) | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках, и способы их применения | |
| UA120264C2 (uk) | Сполука для застосування в способі лікування імунодефіциту сd4-т клітин у суб'єкта | |
| US8097428B2 (en) | Monoclonal antibodies and their use | |
| Patterson et al. | Prostaglandin E₂ impacts multiple stages of the natural killer cell antitumor immune response | |
| Jiang et al. | Intact CD100–CD72 interaction necessary for TCR-induced T cell proliferation | |
| ES2808947T3 (es) | Anticuerpos humanizados anti-BAG3 | |
| US12116415B2 (en) | Anti-BCMA antibodies | |
| Guillaume et al. | Lung B cells in ectopic germinal centers undergo affinity maturation | |
| RU2015150723A (ru) | Моноклональное антитело против cxcr5 | |
| Yamamoto et al. | Vascular changes in bleomycin‐induced scleroderma | |
| Del Padre et al. | Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia | |
| Théry et al. | ISEV2018 abstract book |